Dose-escalation Study of Safety of PBCAR0191 in Patients With r/r NHL and r/r B-cell ALL
Status:
Recruiting
Trial end date:
2022-06-01
Target enrollment:
Participant gender:
Summary
This is a Phase 1/2a, nonrandomized, open-label, parallel assignment, dose-escalation, and
dose-expansion study to evaluate the safety and clinical activity of PBCAR0191 in adults with
r/r B ALL (Cohort A) and in adults with r/r B-cell NHL (Cohort N).